Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma-Reference-Cited by-同舟云学术

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

Published:2020-04-23 Issue:14 Volume:26 Page:3546-3556
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gordon Leo I.^ORCID,Kaplan Jason B.,Popat Rakesh,Burris Howard A.,Ferrari Silvia^ORCID,Madan Sumit,Patel Manish R.,Gritti Giuseppe^ORCID,El-Sharkawi Dima^ORCID,Chau Ian^ORCID,Radford John A.,Pérez de Oteyza Jaime^ORCID,Zinzani Pier Luigi,Iyer Swaminathan,Townsend William,Karmali Reem,Miao Harry,Proscurshim Igor,Wang Shining,Wu Yujun,Stumpo Kate^ORCID,Shou Yaping,Carpio Cecilia^ORCID,Bosch Francesc^ORCID

Funder

Millenium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of takeda Pharmaceutical Company Limited

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

2. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors;ESMO Open;2024-06

3. Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials;Frontiers in Pharmacology;2024-05-17

4. Upregulation of miR-96-5p Expression Inhibits Malignant Progression in T-cell Acute Lymphoblastic Leukemia by Targeting Spleen Tyrosine Kinase;J BIOL REG HOMEOS AG;2024

5. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors;Cancer Medicine;2024-03